Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response

A. Rody*, T. Karn, R. Gätje, A. Ahr, C. Solbach, K. Kourtis, M. Munnes, S. Loibl, S. Kissler, E. Ruckhäberle, U. Holtrich, G. v. Minckwitz, M. Kaufmann

*Corresponding author for this work
60 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response'. Together they form a unique fingerprint.

Medicine & Life Sciences